Part:BBa_K4808002
ilvA*
ilvA* is the mutation of ilvA BBa_K4808001. In E.coli, IIe will have inhibition effect towards the production of threonine dehydratase encoded by ilvA. It will reduce the activity of this enzyme and further reduce the production of a-KB, which is our target product. As a result, we mutated ilvA to eliminate the effect of lle on it.
Characterization
For further improvement on a-kb production levels, we want to optimize threonine's conversion into a-kb, a key step in a-kb production.We tried to use plasmids with different copy numbers to express ilvA to determine the effect on copy number on a-KB production. Thus, we constructed ilvA onto a new plasmid p321-ilvA, which has a low copy number in E. coli (Figure A)
We also mutated ilvA(obtainning ilvA*) to make its expressed enzymes resistant to the inhibition of Isoleucine. Isoleucine is a downstream product of a-kb.Our gene knock out choices do not completely obstruct the pathway continuing downwards of a-kb, thus meaning that Isoleucine is existent in the E.coli cell (Isoleucine inhibits ilvA expressed Threonine Dehydrase, thus negatively affecting Threonine's conversion into a-kb, which is reported in many papers).
We made four base mutations in ilvA (i.e., C1339T, G1341T, C1351G, T1352C), which substitutes the 447th and 451th amino acids (both Leu) into Phe and Ala, respectively (Figure B). After successfully mutating the ilvA gene through PCR with primers coding for the mutated sequences (Figure C), we obtained the strains pw1-ilvA* and p321-ilvA* (ilvA* is the mutated ilvA). The two plasmids, along with pw1-ilvA and p321-ilvA, were transformed into AIS-2, and the a-kb production is measured. The result show that pw1-ilvA* strain was most efficient. Moreover, we found that for both vectors (p321 and pw1), the mutated ilvA* yielded more a-KB compared to the non-mutated ilvA, and no matter whether ilvA is mutated or not, the pw1 plasmid with higher copy number yielded more a-KB than the p321 plasmid with low copy number.
Figure: (A) the different copy number of plasmid with ilvA. (B) ilvA*'s resistancy to isoleucine inhibition and codon and amino acid differences between the ilvA and the mutated ilvA*. (C) the design for the mutation of ilvA and the sequencing results of ilvA*. (D)the a-kb production of strain AIS-2 with four different plasmid;
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal EcoRI site found at 1315
- 12INCOMPATIBLE WITH RFC[12]Illegal EcoRI site found at 1315
- 21INCOMPATIBLE WITH RFC[21]Illegal EcoRI site found at 1315
- 23INCOMPATIBLE WITH RFC[23]Illegal EcoRI site found at 1315
- 25INCOMPATIBLE WITH RFC[25]Illegal EcoRI site found at 1315
- 1000INCOMPATIBLE WITH RFC[1000]Illegal SapI.rc site found at 1168
| None |